Brief: Orexo Sees Positive EBITDA In 2024

Orexo AB

08/02/2024 08:42

Feb 8 (Reuters) - Orexo AB  ORX.ST :
    * 2024 OUTLOOK: BUPRENORPHINE/NALOXONE MARKET WILL GROW 2-5
PERCENT, BASED ON CURRENT GROWTH TRAJECTORY
    * 2024 OUTLOOK: ZUBSOLV NET SALES IN USD WILL BE IN LINE
WITH 2023
    * 2024 OUTLOOK: COST CONTROL IS A PRIORITY AND OPEX
EXCLUDING
DEPRECIATION AND AMORTIZATION WILL DECLINE FROM SEK 582 M IN
2023 TO BELOW SEK 530 M IN 2024
    * 2024 OUTLOOK: POSITIVE EBITDA FOR FY 2024

Source text for Eikon:  ID:nWkrqW6yC 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))